Ahmedabad-based CDMO and private-label manufacturer of generic pharma formulations — tablets, capsules, oral liquids, powders and external preparations — sold domestically and exported to 30+ countries.
Reported
Each figure keeps its basis and period; nothing is filled in.
| Metric | Value | Change | Basis | Period | Note |
|---|---|---|---|---|---|
| Revenue | 45.9 | +18.2% YoY | Quarterly, as filed | Quarter to Mar 2026 | Revenue from operations as filed. |
| Operating margin | 17.2 | −2.3 pts YoY | Operating profit / revenue | Quarter to Mar 2026 | For the quarter; a change is in percentage points. |
| Net profit | 4.9 | +13.6% YoY | Quarterly, as filed | Quarter to Mar 2026 | Profit after tax as filed. |
| Return on equity | −37.7 pts | Trailing twelve months | TTM · period unavailable | Not in the analysed materials. No older figure is substituted. | |
| Free cash flow margin | -25.73 | −21.8 pts | Fiscal year | FY ending Mar 2026 | (Operating cash flow − fixed-asset purchases + disposals) ÷ revenue. |
| Revenue growth (YoY) | −273.6 pts | Trailing twelve months | TTM · period unavailable | Not in the analysed materials. No older figure is substituted. |
Guidance
5 targets tracked, none judged yet · 5 open · verdicts reflect calls analysed to Q2 FY26.
| Target | Original wording | Said | Latest call | Verdict |
|---|---|---|---|---|
| Revenue Growth | Maintain same momentum as H1 FY26 (135.59% YoY) for upcoming 6 months and later years | Q2 FY26 | Guidance issued during Q2 FY26 call. | New |
5 of Accretion Pharmaceuticals Ltd's 5 targets are still open. See which are on track and which have gone quiet. The 1 above are the free sample; 4 more targets are in the full ledger.
Claimed
Qualified
Price
1Y: ₹57.85 on 24 Oct 2025 → ₹185. High ₹219 (15 Sept 2026), low ₹55.15 (6 Nov 2025).
Overview
Based on the company's own presentations, annual report and earnings calls.
Accretion Pharmaceuticals is a contract development and manufacturing organization (CDMO) that makes generic and branded pharmaceutical formulations across five dosage forms — tablets, capsules, oral liquids, oral powders and external preparations — spanning therapeutic areas such as antibiotics, anti-inflammatory, antihistamine, cardiac and anti-diabetic. It earns revenue mainly through contract manufacturing / sales-loan-license arrangements for other pharma companies, supplemented by direct domestic sales and direct exports. Manufacturing is done at a single WHO-cGMP certified facility in Ahmedabad, Gujarat, and the company sells across more than 16 Indian states and exports (directly and via merchant exporters) to over 30 countries in Africa, Southeast Asia and Latin America.
Segments
close before → close after
The move from the last close before each results date to the first close after it — the market's first read on the quarter, not the quarter itself.
Guidance
5 targets tracked, none judged yet · 5 open · verdicts reflect calls analysed to Q2 FY26.
| Target | Original wording | Said | Latest call | Verdict |
|---|---|---|---|---|
| Revenue Growth | Maintain same momentum as H1 FY26 (135.59% YoY) for upcoming 6 months and later years | Q2 FY26 | Guidance issued during Q2 FY26 call. | New |
Claimed
Qualified
The full ledger
A free account opens 5 company ledgers a month. All 5 tracked commitments, with each call’s wording and source.
Call summaries
ACCPL Q2 FY26
Accretion Pharmaceuticals delivered strong H1 FY26 results, with significant revenue and PAT growth driven by IPO-funded capacity expansion and strategic focus on CDMO and export markets. While EBITDA margins saw a temporary compression due to scaling costs, management is confident in recovery as the business matures. The company is aggressively pursuing product and plant registrations in new geographies to sustain future growth.
Read the full callEvery analysed call
Fundamentals
Current values with the period they cover; the trend reads across the 3 fiscal years held (Mar 2024 to Mar 2026).
Financials
Net profit, year on year: +14% (quarter to mar 2026 against mar 2025).
| Line item | Mar 2024 | Sept 2024 | Mar 2025 | Sept 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Sales | 13 | 19 | 39 | 44 | 46 |
| Expenses | 11 | 14 | 31 | 37 | 38 |
| Operating profit | 3 | 4 | 8 | 7 | 8 |
| Operating margin | 19.3% | 23.3% | 19.4% | 16.2% | 17.2% |
| Other income | 0 | 0 | 0 | 0 | 0 |
| Interest | 0 | 1 | 1 | 0 | 0 |
| Depreciation | 0 | 0 | 0 | 0 | 1 |
| Profit before tax | 2 | 3 | 6 | 6 | 7 |
| Tax rate | 25.0% | 25.2% | 33.1% | 25.9% | 26.2% |
| Net profit | 1 | 2 | 4 | 5 | 5 |
| EPS (₹ per share) | 3.72 | 3.01 | 5.30 | 4.27 | 4.43 |
| Line item | Mar 2024 | Mar 2025 | Sept 2025 | Mar 2026 |
|---|---|---|---|---|
| Equity capital | 4 | 8 | 11 | 11 |
| Reserves | 1 | 7 | 35 | 44 |
| Borrowings | 13 | 14 | 8 | 12 |
| Other liabilities | 8 | 10 | 5 | 10 |
| Total liabilities | 27 | 40 | 59 | 77 |
| Fixed assets | 5 | 6 | 9 | 13 |
| Capital work in progress | 0 | 0 | 0 | 0 |
| Investments | 0 | 0 | 0 | 0 |
| Other assets | 22 | 34 | 50 | 63 |
| Total assets | 27 | 40 | 59 | 77 |
| Line item | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|
| Cash from operations | -12 | -1 | -15 |
| Cash from investing | -5 | -2 | -9 |
| Cash from financing | 17 | 2 | 27 |
| Net cash flow | 0 | -0 | 4 |
| Free cash flow | -17 | -2 | -23 |
| Line item | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|
| Debtor days | 159 | 74 | 91 |
| Inventory days | 564 | 188 | 159 |
| Days payable | 256 | 69 | 32 |
| Cash conversion cycle | 466 | 193 | 218 |
| Working capital days | 189 | 65 | 145 |
| Return on capital employed | — | 46.4% | 28.9% |
| Dividend payout | 0.0% | 0.0% | 0.0% |
Ownership
Promoters hold 73.52% as of Jun 2026; institutions added 2.76 pts since Mar 2026.
since Mar 2026
Disclosed holders that added to a position or appeared on the register for the first time, biggest addition first.
The same filing shows 0 holders trimming and 1 off the list — both are in the register beside this.
Named in the Jun 2026 filing
Every holder of Accretion Pharmaceuticals Ltd above SEBI's 1% disclosure line, and what changed since Mar 2026.
| Holder | Stake | Change |
|---|---|---|
| 17.69% | unchanged | |
| 17.69% | unchanged | |
| 17.69% | unchanged | |
| 17.69% | unchanged | |
| AIF | 2.76% | newly disclosed |
| 0.68% | unchanged | |
| 0.68% | unchanged | |
| 0.68% | unchanged | |
| 0.68% | unchanged | |
| 0.02% | unchanged | |
| — | off the list |
A holder disappearing from this list has fallen below the 1% line — it is not necessarily a sale. Percentages are of total shares, as disclosed in the company's own filing. Who was buying across the market this quarter.
Your own record
Free account: one company. Everything above stays public.
Write why you follow Accretion Pharmaceuticals Ltd and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading
Guides on how to read this kind of business and the numbers that matter.
